FDC launches Favipiravir oral suspension to treat Covid-19 in India

Pharma firm FDC Ltd on Monday said it has launched oral suspension of Favipiravir to treat mild to moderate cases of COVID-19 in the country.

Topics
Coronavirus | Coronavirus Tests | Coronavirus Vaccine

Press Trust of India  |  New Delhi 

Pharma firm FDC Ltd on Monday said it has launched oral suspension of Favipiravir to treat mild to moderate cases of COVID-19 in the country.

This prescription-only Favenza oral suspension is currently available at all retail medical outlets and hospital pharmacies across India, FDC said in a statement.

Convenient loading dosage of the oral suspension helps reduce dosage frequency, it added.

"With positive cases on the rise again, now is the time to provide healthcare warriors in our country with viable options in this continuous battle against this disease.

In order to combat COVID-19, we believe in offering best efficacy along with convenience to our patients and as such we have focused our efforts in making the process of COVID-19 treatment hassle-free," FDC Business Development & Commercial Excellence General Manager Mayank Tikkha said.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Read our full coverage on Coronavirus
First Published: Mon, July 12 2021. 16:23 IST
RECOMMENDED FOR YOU